VHIO is participating prominently in a study that seeks to evaluate the efficacy of a novel combination therapy in advanced pancreatic cancer

by Vall d’Hebron

The biopharmaceutical company Ability Pharmaceuticals, SL today announced the inclusion of the first patients in a phase 2b clinical trial with its novel autophagy-inducer anticancer compound ABTL0812...

Read more

Ability Pharmaceuticals Announces FDA-Orphan Drug Designation for ABTL0812 in Biliary Tract Cancer

by AbilityPharma

Ability Pharmaceuticals, a drug development biopharmaceutical company specialized in oncology, announced today that it has received orphan-drug designation (ODD) for ABTL0812 from the US Food and Drug...

Read more
Subscribe to Directory
Write an Article

Recent News

¿Por qué no es recomendable llevar la ...

La mejor actitud que podemos adoptar es la de trat...

Exposure to Heat and Cold During Pregnan...

The research team observed changes in head circumf...

Using mobile RNAs to improve Nitrogen a...

AtCDF3 gene induced greater production of sugars a...

Highlight

Eosinófilos. ¿Qué significa tener val...

by Labo'Life

​En nuestro post hablamos sobre este interesante tipo de célula del...

Rethinking Alzheimer’s clinical trials...

by Fundació Clínic per a la Recerca Biomèdica

A paper published in Alzheimer’s & Dementia: The Journal of the Alzh...

Photos Stream